Andrea Best | Executive Medical Director, Pharmacovigilance and Patient Safety
AbbVie

Andrea Best, Executive Medical Director, Pharmacovigilance and Patient Safety, AbbVie

Dr. Andrea Best is an Executive Medical Director in Pharmacovigilance and Patient Safety at AbbVie in the suburbs of Chicago where she is responsible for Clinical Trial Safety Excellence.  Andrea has over 20 years of experience in academia and industry across a variety of roles (clinical development, medical affairs and pharmacovigilance) and spanning numerous therapeutic areas including  oncology, immunology, anti-infectives, renal, anesthesia, general medicine and devices. Most recently, Andrea was responsible for oversight of the safety team leaders and safety strategy for all  products in AbbVie’s portfolio comprising both marketed and development  products.  She has led discussions with global regulatory authorities on a variety of issues and has participated on several external collaborations related to regulatory system strengthening and pharmacovigilance in developing countries.  Prior to joining AbbVie, Andrea was an Assistant Professor of Medicine at Loyola Stritch School of Medicine and an attending physician in the Chicago Cook County Hospital system.  Andrea has her medical degree from Midwestern University and holds a Master’s Degree in Public Health in Epidemiology from the University of Michigan.  In addition, she has a strong interest in health policy and has completed her PhD coursework in Health Policy and Administration at the University of Illinois.  Andrea lives with her husband and two teenage children in the suburbs of Chicago and in her free time enjoys spending time with her family, playing tennis and scuba diving.

Appearances:



Drug Safety World Day 2 @ 11:30

Navigating the complexities of reference safety information regulation: How to react to the latest guidance’s in GRFG RSI

  • Review of the November 2017 clinical trial facilitation group reference safety information question and answer document
  • Discussion of reference safety information complexities and navigating the changing environment
  • Perspectives on operationalizing reference safety information in the setting of global clinical trial conduct

Drug Safety World Day 2 @ 14:20

Cooperative approaches to developing pharmacovigilance strategies in emerging markets

  • The importance of post-market safety surveillance in global health programs- where have we been missing the mark?
  • Cooperative Approaches to developing PV systems in LMIC’s – working with local health systems to reduce ADEs  
  • Thinking outside the box- challenges and solutions to developing reporting systems across pharmaceutical companies in different LMIC’s- lessons learnt

back to speakers